Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Obsidian Therapeutics
Biotech
Former Arena CEO takes over new RNA biotech—Chutes & Ladders
Former Arena CEO to lead new RNA-focused biotech. Larkspur launches with all-woman leadership. CytoDyn's president takes medical leave of absence.
Max Bayer
May 26, 2023 9:30am
Bristol Myers inks extension to Obsidian cell therapy pact
Oct 27, 2022 10:25am
Obsidian bags $115M to untether cell therapy from toxic sidekick
Sep 9, 2021 8:00am
Vertex taps Obsidian in controllable genetic medicines deal
Apr 22, 2021 10:23am
Bristol Myers exercises option on Obsidian's CD40L cell therapy
Sep 15, 2020 9:25am
Gilman buckles in as Arrakis raises $75M—Chutes & Ladders
Apr 19, 2019 9:30am
